Holen Sie sich die Stockscreener-App
5.50
3.51%
-0.20
Handel nachbörslich:
5.51
0.010
+0.18%
Schlusskurs vom Vortag:
$5.70
Offen:
$5.73
24-Stunden-Volumen:
93,632
Relative Volume:
1.07
Marktkapitalisierung:
$35.49M
Einnahmen:
$5.75M
Nettoeinkommen (Verlust:
$-38.96M
KGV:
-0.4411
EPS:
-12.47
Netto-Cashflow:
$-32.63M
1W Leistung:
+0.46%
1M Leistung:
+36.14%
6M Leistung:
-28.48%
1J Leistung:
-19.83%
1-Tages-Spanne:
$5.40
$6.01
1-Wochen-Bereich:
$5.40
$6.30
52-Wochen-Spanne:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Firmenname
Kala Bio Inc
Sektor
Branche
Telefon
781-996-5252
Adresse
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Vergleichen Sie KALA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
5.50 | 35.33M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-03-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Herabstufung | Jefferies | Buy → Hold |
| 2020-07-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-27 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Kala Bio Inc Aktie (KALA) Neueste Nachrichten
What analysts say about KALA BIO Inc. stockSuperior portfolio returns - jammulinksnews.com
Is CURR a good long term investmentDynamic investment growth - jammulinksnews.com
KALA BIO Inc. Stock Analysis and ForecastJaw-dropping returns - jammulinksnews.com
Is KALA BIO Inc. a good long term investmentUnmatched profit growth - Autocar Professional
KALA BIO (NASDAQ:KALA) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
What makes KALA BIO Inc. stock price move sharplyHigh Return Conservative Stocks - Newser
Why KALA BIO Inc. stock attracts strong analyst attentionMomentum Buy Alert - Newser
How KALA BIO Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
All Eyes On KALA's CHASEWill The PCED Trial Make Its Case? - RTTNews
Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis - Ophthalmology Times
LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA) - Defense World
KALA Bio completes enrollment of CHASE clinical trial - Ophthalmology Times
KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target - MarketScreener
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News - GuruFocus
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg - GuruFocus
Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect - MarketScreener
KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KP - GuruFocus
Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial - TipRanks
Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder - Investing.com
KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025 - Quiver Quantitative
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
KALA BIO Eyes 100,000 Patient Market as Pivotal PCED Trial Completes Enrollment, Q3 Results Ahead - Stock Titan
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discu - GuruFocus
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Yahoo Finance
KALA BIO Executives Sell Shares Under 10b5-1 Plans - TradingView
Millennium Management LLC Purchases 17,130 Shares of HBT Financial, Inc. (NASDAQ:HBT) - Defense World
Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Nexa Resources S.A. (NYSE:NEXA) Shares Sold by Millennium Management LLC - Defense World
24,353 Shares in T. Rowe Price Floating Rate ETF (NYSEARCA:TFLR) Acquired by Bank of America Corp DE - Defense World
Cadre Holdings, Inc. (NYSE:CDRE) Shares Acquired by Millennium Management LLC - Defense World
Bank of America Corp DE Acquires 2,612 Shares of First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) - Defense World
Millennium Management LLC Sells 1,791 Shares of Bluerock Homes Trust, Inc. (NYSEAMERICAN:BHM) - Defense World
Ameriprise Financial Inc. Buys 11,012 Shares of Liberty All-Star Growth Fund, Inc. (NYSE:ASG) - Defense World
Kala Bio director Mark Iwicki sells $40,638 in stock By Investing.com - Investing.com South Africa
Kala Bio director Mark Iwicki sells $40,638 in stock - Investing.com India
KALA BIO Executives Sell Shares - TradingView
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
KALA BIO (NASDAQ:KALA) Given “Outperform” Rating at Oppenheimer - Defense World
KALA: Oppenheimer Announces Outperform Rating for Kala Bio | KALA Stock News - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | KALA Stock News - GuruFocus
Tidal Investments LLC Has $269,000 Stake in Air Lease Co. (NYSE:AL) - Defense World
Aegon Ltd. (NYSE:AEG) Shares Sold by Millennium Management LLC - Defense World
KALA BIO to Present at Jefferies Global Healthcare Conference - The Manila Times
KALA BIO to Reveal Latest Eye Disease Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan
Finanzdaten der Kala Bio Inc-Aktie (KALA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):